Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2557331 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| SCHEMBL1839092 | 0.86 | KDM4E (0.54) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| SCHEMBL11368920 | 0.86 | MAPT (0.57) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| Hydrochloric Acid SCHEMBL1403100 | 0.85 | KDM4E (0.53) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| SCHEMBL25167821 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| SCHEMBL1162352 | 0.81 | TDP1 (0.56) | ALDH1A1KDM4EMAPTTDP1POLB | |
| SCHEMBL10105366 | 0.81 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTNPC1POLB | |
| SCHEMBL2390452 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTTDP1NPC1 | |
| Oxalic Acid SCHEMBL20984714 | 0.81 | CYP1A2 (0.53) | ALDH1A1KDM4EMAPTNPC1POLB | |
| Hydrochloric Acid SCHEMBL2512014 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4EMAPTTDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | RESPIVERT LTD (GB) | 2013-02-14 | — | — | US | disclosed |
| WO-2011158044-A2 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011124930-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| US-6831079-B1 | Oral delivery; nitrogen triheterocyclic active material, surfactant, polyethylene glycol with sucrose fatty acid esters and/or polyvinylpyrrolidone | AMERICAN CYANAMID COMPANY | 2004-12-14 | — | — | US | disclosed |
| EP-1000062-B1 | TRICYCLIC VASOPRESSIN AGONISTS | WYETH CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | disclosed |
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | ALDH1A1 869/4885KDM4E 4101/4885MAPT 2321/4885 |
| US-20130040962-A1 | P38 MAP Kinase Inhibitors | MAPK15, MAPK1, MAP3K15 | ALDH1A1 1479/4885KDM4E 3646/4885MAPT 890/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | ALDH1A1 869/4885KDM4E 4101/4885MAPT 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.